Font

Aa Aa Aa

Background color

A A

Site version

Color Black and white
Drugs

Aciclovir-Darnitsa

Systemic antiviral drugs

Aciclovir is a synthetic analogue of purine nucleoside with in vivo and in vitro inhibitory activity against human herpes virus, including herpes simplex type 1 and 2, varicella zoster virus and herpes zoster, Epstein-Barr virus, and cytomegalovirus. In cell culture, aciclovir is most effective against herpes simplex type 1 and 2, and then, in decreasing order of activity, against varicella zoster virus and herpes zoster, Epstein-Barr virus, and cytomegalovirus.

– Treatment of infections of skin and mucous membranes caused by Herpes simplex virus, including primary and recurrent genital herpes
– Preventing recurrence of infections caused by Herpes simplex virus in patients with normal immunity
– Preventing infections caused by Herpes simplex virus in patients with an immunodeficiency
– Treatment of infections caused by Varicella zoster virus (chickenpox, herpes zoster)

The tablets should be taken whole with water. When high doses of the drug are used, adequate hydration of the patient should be maintained.

Adults.

Treatment of infections caused by Herpes simplex virus.

Aciclovir-Darnitsa is used as 200 mg 5 times per day with approximately 4-hour intervals, apart from nighttime. The treatment duration is 5 days; however, in case of severe primary infection, it can be extended.

If necessary, in patients with severe immunodeficiency (e.g., after bone marrow transplant) or with decreased intestinal absorption, the single dose can be doubled to 400 mg or an appropriate intravenous dose used.

Treatment should be started as soon as possible after infection develops. In case of recurrent herpes, it is better to start treatment during the prodromal period or after the first signs of skin lesions.

Preventing recurrence of infections caused by Herpes simplex virus in patients with normal immunity.

Specialized edition for medical institutions and doctors.